Ratings SANA AB

Equities

SANION

SE0005794617

Market Closed - Nasdaq Stockholm Other stock markets 17:00:00 20/06/2024 BST			5-day change	1st Jan Change
3.395 ^SEK	-9.47%		-17.80%	-15.34%

06-13	Transcript : Saniona AB - Special Call
05-29	Saniona AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Over the last twelve months, the sales forecast has been frequently revised upwards.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
SANA AB	-15.34%	36.08M	-	D+
VERTEX PHARMACEUTICALS INCORPORATED	+15.34%	122B		B+
REGENERON PHARMACEUTICALS, INC.	+20.40%	113B		B+
ARGENX SE	+8.24%	22.84B		B
BIONTECH SE	-19.79%	20.72B		B+
GENMAB A/S	-16.19%	16.51B		A-
BEIGENE, LTD.	-13.58%	16.39B		B
WUXI APPTEC CO., LTD.	-44.35%	15.83B		A-
NEUROCRINE BIOSCIENCES, INC.	+2.75%	13.49B		C+
SAREPTA THERAPEUTICS, INC.	+66.95%	11.67B		C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes